Details of the Drug Combination

General Information of Drug Combination (ID: DCGUCD8)

Drug Combination Name

Amonafide Arfolitixorin

Indication

Disease Entry	Status	REF
Carcinoma	Investigative	[1]

Component Drugs

Amonafide DMAH59S

Arfolitixorin DMIXMYK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: RXF 393

Zero Interaction Potency (ZIP) Score: 1.47

Bliss Independence Score: 3.05

Loewe Additivity Score: 5.62

LHighest Single Agent (HSA) Score: 7.27

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DC42ODQ	HL-60(TB)	Investigative	[4]
Anaplastic large cell lymphoma	DCW9VC2	SR	Investigative	[4]
Glioma	DCBQIM9	SF-268	Investigative	[4]
Large cell lung carcinoma	DCH6E61	NCI-H460	Investigative	[4]
Malignant melanoma	DCE28IS	LOX IMVI	Investigative	[4]
Colon adenocarcinoma	DC6KQ78	COLO 205	Investigative	[1]
Colon carcinoma	DCZLLFO	KM12	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2	ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.